Early hepatic decompensation is associated with mortality in patients with HCC treated with atezolizumab plus bevacizumab or durvalumab plus tremelimumab
Publication date: December 2026 Source: Seminars in Oncology, Volume 53, Issue 6 Author(s): Margherita Rimini, Simone Rocchetto, Eleonora Alimenti, Giuseppe Cabibbo, Lorenza Rimassa, David J. Pinato, Alessandro Vitale, Francesca R. Ponziani, Silvia Camera, Mara Persano, Pietro Lampertico, Andrea Casadei-Gardini, Massimo Iavarone
Early hepatic decompensation is associated with mortality in patients with HCC treated with atezolizumab plus bevacizumab or durvalumab plus tremelimumab. // Seminars in Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S0093775426001065?dgcid=rss_sd_all
Early hepatic decompensation is associated with mortality in patients with HCC treated with atezolizumab plus bevacizumab or durvalumab plus tremelimumab. Seminars in Oncology. https://www.sciencedirect.com/science/article/pii/S0093775426001065?dgcid=rss_sd_all
“Early hepatic decompensation is associated with mortality in patients with HCC treated with atezolizumab plus bevacizumab or durvalumab plus tremelimumab.” Seminars in Oncology.
@article{article65824,
title = {Early hepatic decompensation is associated with mortality in patients with HCC treated with atezolizumab plus bevacizumab or durvalumab plus tremelimumab},
journal = {Seminars in Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S0093775426001065?dgcid=rss_sd_all}
}